• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

确定小林、佐野和江上标准与伊朗川崎病患儿静脉注射免疫球蛋白抵抗及冠状动脉瘤患病率之间的关系。

Determination of the Relationship Between Kobayashi, Sano, and Egami Criteria and Prevalence of Intravenous Immunoglobulin Resistance and Coronary Artery Aneurysm in Iranian Children with Kawasaki Disease.

作者信息

Shashaani Niloufar, Shiari Reza, Karimi Abdullah, Salehi Shima, Ghanaei Roxana, Hassas Yeganeh Mehrnoush, Shiari Sara, Rahmani Khosro, Javadi Parvaneh Vadood

机构信息

Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Department of Pediatric Rheumatology, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

出版信息

Open Access Rheumatol. 2020 Aug 26;12:187-192. doi: 10.2147/OARRR.S255138. eCollection 2020.

DOI:10.2147/OARRR.S255138
PMID:32943952
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7473984/
Abstract

INTRODUCTION

Kawasaki disease (KD) is a systemic vasculitis that occurs mostly in children under five years old. Kawasaki affects the middle-size arteries, especially the coronary arteries. Therefore, without adequate treatment, it may cause coronary artery aneurysm in 25% of patients. The purpose of this study was to investigate the relationship between Kobayashi, Sano, and Egami criterions with coronary artery aneurysm in KD patients during the last ten years and to identify risk factors in patients with intravenous immunoglobulin (IVIG)-resistant and coronary artery aneurysms.

METHODOLOGY

Medical records of 363 Kawasaki patients referred during 2008-2017 were reviewed. Patients' demographic data and Kobayashi, Sano, and Egami scores of each patient were calculated. Based on echocardiographic findings, cases of coronary artery aneurysm were determined. Sensitivity, specificity, positive and negative predictive value, and the accuracy of each criterion were determined to predicting IVIG resistance and detect coronary artery aneurysm.

RESULTS

There was a slight relationship between IVIG-resistance in Kawasaki children and its prediction based on the Kobayashi risk score, but no relationship was found between the Egami and Sano criteria. Sixty-three patients (17.4%) had coronary artery lesions (CALs) on time of diagnosis. There were no statistically significant differences between gender and mean age of children with and without CALs. Also, there was no significant relationship between coronary artery aneurysm in Kawasaki children and its prediction based on the above three risk factors. The area under the ROC-curve of all three risk measures of Kobayashi, Egami, and Sano indicated that all three criteria were not useful in predicting CALs.

CONCLUSION

Despite the low accuracy of the three above criteria to predictive of patients with IVIG resistance, it seems that the variables of age, duration of fever, and C-reactive protein (CRP) are more useful than other variables and may be utilized to evaluate patients by establishing a more appropriate cut-off point.

摘要

引言

川崎病(KD)是一种主要发生在5岁以下儿童的全身性血管炎。川崎病会影响中等大小的动脉,尤其是冠状动脉。因此,若未得到充分治疗,25%的患者可能会出现冠状动脉瘤。本研究的目的是调查过去十年间小林、佐野和江上标准与川崎病患者冠状动脉瘤之间的关系,并确定静脉注射免疫球蛋白(IVIG)抵抗且患有冠状动脉瘤的患者的风险因素。

方法

回顾了2008年至2017年期间转诊的363例川崎病患者的病历。计算了患者的人口统计学数据以及每位患者的小林、佐野和江上评分。根据超声心动图检查结果确定冠状动脉瘤病例。确定了各标准预测IVIG抵抗和检测冠状动脉瘤的敏感性、特异性、阳性和阴性预测值以及准确性。

结果

川崎病患儿的IVIG抵抗与其基于小林风险评分的预测之间存在轻微关系,但江上和佐野标准之间未发现关系。63例患者(17.4%)在诊断时患有冠状动脉病变(CALs)。有CALs和无CALs的儿童在性别和平均年龄上无统计学显著差异。此外,川崎病患儿的冠状动脉瘤与其基于上述三个风险因素的预测之间也无显著关系。小林、江上和佐野所有三个风险指标的ROC曲线下面积表明,这三个标准对预测CALs均无用。

结论

尽管上述三个标准预测IVIG抵抗患者的准确性较低,但年龄、发热持续时间和C反应蛋白(CRP)等变量似乎比其他变量更有用,通过建立更合适的切点,可用于评估患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef25/7473984/7b08ebc05b72/OARRR-12-187-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef25/7473984/7b08ebc05b72/OARRR-12-187-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef25/7473984/7b08ebc05b72/OARRR-12-187-g0001.jpg

相似文献

1
Determination of the Relationship Between Kobayashi, Sano, and Egami Criteria and Prevalence of Intravenous Immunoglobulin Resistance and Coronary Artery Aneurysm in Iranian Children with Kawasaki Disease.确定小林、佐野和江上标准与伊朗川崎病患儿静脉注射免疫球蛋白抵抗及冠状动脉瘤患病率之间的关系。
Open Access Rheumatol. 2020 Aug 26;12:187-192. doi: 10.2147/OARRR.S255138. eCollection 2020.
2
Evaluating the performance of egami, kobayashi and sano scores in predicting IVIG resistance in infant kawasaki disease.评估 egami、小林和佐野评分在预测婴儿川崎病 IVIG 抵抗中的表现。
BMC Pediatr. 2024 Sep 28;24(1):606. doi: 10.1186/s12887-024-05035-z.
3
Japanese Kawasaki Disease Scoring Systems: Are they Applicable to the Iranian Population?日本川崎病评分系统:它们适用于伊朗人群吗?
Arch Iran Med. 2020 Jan 1;23(1):31-36.
4
Verification of risk scores to predict i.v. immunoglobulin resistance in incomplete Kawasaki disease.验证预测不完全川崎病静脉注射免疫球蛋白抵抗的风险评分
Pediatr Int. 2016 Feb;58(2):146-51. doi: 10.1111/ped.12755. Epub 2015 Dec 3.
5
Evaluation of Formosa score and diagnostic sensitivity and specificity of four Asian risk scores for predicting intravenous immunoglobulin resistance in Kawasaki disease: a bivariate meta-analysis.福尔摩沙评分及四种亚洲风险评分对川崎病静脉注射免疫球蛋白抵抗预测的诊断敏感性和特异性评估:双变量荟萃分析
Front Cardiovasc Med. 2023 Jun 12;10:1164530. doi: 10.3389/fcvm.2023.1164530. eCollection 2023.
6
Inability of Asian risk scoring systems to predict intravenous immunoglobulin resistance and coronary lesions in Kawasaki disease in an Italian cohort.亚洲风险评分系统无法预测意大利队列川崎病患者静脉注射免疫球蛋白耐药和冠状动脉病变。
Eur J Pediatr. 2019 Mar;178(3):315-322. doi: 10.1007/s00431-018-3297-5. Epub 2018 Nov 29.
7
Risk factors in IVIG-resistant Kawasaki disease and correlation with Japanese scoring systems - a study from Eastern India.静脉注射免疫球蛋白抵抗型川崎病的危险因素及其与日本评分系统的相关性——一项来自印度东部的研究
Clin Rheumatol. 2023 Jan;42(1):145-150. doi: 10.1007/s10067-022-06344-3. Epub 2022 Sep 2.
8
Comparison of Risk-Scoring Systems in Predicting Kawasaki Disease Associated Coronary Artery Dilation in a North American Cohort.北美队列中预测川崎病相关冠状动脉扩张的风险评分系统比较
Pediatr Cardiol. 2024 Aug 4. doi: 10.1007/s00246-024-03611-9.
9
Usefulness of Kawasaki disease risk scoring systems to the Turkish population.川崎病风险评分系统在土耳其人群中的应用。
Anatol J Cardiol. 2020 Aug;24(2):97-106. doi: 10.14744/AnatolJCardiol.2020.37560.
10
A comparison of the predictive validity of the combination of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio and other risk scoring systems for intravenous immunoglobulin (ivig)-resistance in Kawasaki disease.中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值联合应用及其他风险评分系统对川崎病静脉注射免疫球蛋白(IVIG)抵抗的预测效度比较。
PLoS One. 2017 May 23;12(5):e0176957. doi: 10.1371/journal.pone.0176957. eCollection 2017.

引用本文的文献

1
Establishment and validation of risk prediction model to predict intravenous immunoglobulin-resistance in Kawasaki disease based on meta-analysis of 15 cohorts.基于15个队列的荟萃分析建立和验证预测川崎病静脉注射免疫球蛋白抵抗的风险预测模型
Ital J Pediatr. 2025 Feb 21;51(1):55. doi: 10.1186/s13052-025-01889-w.
2
Intravenous Immunoglobulin in Kawasaki Disease-Evolution and Pathogenic Mechanisms.静脉注射免疫球蛋白治疗川崎病的进展与发病机制
Diagnostics (Basel). 2023 Jul 11;13(14):2338. doi: 10.3390/diagnostics13142338.
3
Epidemiological data of national Kawasaki disease registry in Iran, 2007-2019.

本文引用的文献

1
Profile of resistance to IVIG treatment in patients with Kawasaki disease and concomitant infection.川崎病合并感染患者对静脉注射免疫球蛋白治疗耐药的特征。
PLoS One. 2018 Oct 17;13(10):e0206001. doi: 10.1371/journal.pone.0206001. eCollection 2018.
2
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association.川崎病的诊断、治疗和长期管理:美国心脏协会发布的一份面向医疗保健专业人员的科学声明。
Circulation. 2017 Apr 25;135(17):e927-e999. doi: 10.1161/CIR.0000000000000484. Epub 2017 Mar 29.
3
Coronary Artery Aneurysms in Kawasaki Disease: Risk Factors for Progressive Disease and Adverse Cardiac Events in the US Population.
2007 - 2019年伊朗全国川崎病登记处的流行病学数据。
Front Pediatr. 2023 Jan 11;10:988371. doi: 10.3389/fped.2022.988371. eCollection 2022.
川崎病冠状动脉瘤:美国人群中进展性疾病和不良心脏事件的危险因素。
J Am Heart Assoc. 2016 Sep 15;5(9):e003289. doi: 10.1161/JAHA.116.003289.
4
Predicting IVIG resistance in UK Kawasaki disease.预测英国川崎病患者对静脉注射免疫球蛋白的耐药性。
Arch Dis Child. 2015 Apr;100(4):366-8. doi: 10.1136/archdischild-2014-307397. Epub 2015 Feb 10.
5
Kawasaki disease: pathophysiology, clinical manifestations, and management.川崎病:病理生理学、临床表现和治疗。
Curr Rheumatol Rep. 2014 Jun;16(6):423. doi: 10.1007/s11926-014-0423-x.
6
The epidemiology and clinical features of Kawasaki disease in Australia.澳大利亚川崎病的流行病学和临床特征。
Pediatrics. 2014 Apr;133(4):e1009-14. doi: 10.1542/peds.2013-2936. Epub 2014 Mar 31.
7
Predictors of nonresponse to intravenous immunoglobulin therapy in Kawasaki disease.川崎病静脉注射免疫球蛋白治疗无反应的预测因素
Korean J Pediatr. 2013 Feb;56(2):75-9. doi: 10.3345/kjp.2013.56.2.75. Epub 2013 Feb 25.
8
Epidemiologic features of Kawasaki disease in Japan: results of the 2009-2010 nationwide survey.日本川崎病的流行病学特征:2009-2010 年全国调查结果。
J Epidemiol. 2012;22(3):216-21. doi: 10.2188/jea.je20110126. Epub 2012 Mar 10.
9
Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance.川崎病静脉注射免疫球蛋白抵抗风险评分系统的评估。
J Pediatr. 2011 May;158(5):831-835.e3. doi: 10.1016/j.jpeds.2010.10.031. Epub 2010 Dec 18.
10
Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment.在急性川崎病患者开始初始治疗前预测其对标准高剂量γ-球蛋白治疗无反应的情况。
Eur J Pediatr. 2007 Feb;166(2):131-7. doi: 10.1007/s00431-006-0223-z. Epub 2006 Aug 1.